Beacon Therapeutics is a clinical-stage biotech focused on harnessing gene therapy for severe retinal disorders, notably X-linked retinitis pigmentosa (XLRP) and geographic atrophy. Its lead asset, laru-zova, is in pivotal trials and aims to become a best-in-class treatment for XLRP, with top-line data expected in the second half of 2026. The company estimates that about 14% of the 100,000 U.S. retinitis pigmentosa patients have the X-linked form, underscoring a significant unmet need. Newly raised capital will finance completion of laru-zova’s development and build the commercial infrastructure required for launch. Beacon is also advancing additional pipeline programs for geographic atrophy, an inherited cone-rod dystrophy, and another undisclosed ocular indication. Backed by a syndicate of leading life-science investors, the company remains pre-revenue and relies on venture funding to progress its portfolio.

Total raised

$365M

Funding rounds

3

Latest round

Series C

Latest activity

Jan 2026